Autopsy report · NCT02028312

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

“Per Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Edward Holland, MD

Sponsor type

University, hospital or other

Conditions

Dry Eye Disease

Interventions

Loteprednol etabonate; Artificial Tears; Restasis

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Early Feasibility Study of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System
  “as per sponsor” (81% match in meaning)
• Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed
  “Sponsor related” (78% match in meaning)
• An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
  “Sponsor resource allocation” (76% match in meaning)
• Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
  “Sponsor decision” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.